Michael H. Davidson to Alzheimer Disease
This is a "connection" page, showing publications Michael H. Davidson has written about Alzheimer Disease.
Connection Strength
1.369
-
Plasma lipid levels in Alzheimer's disease patients treated by Donepezil hydrochloride: a cross-sectional study. Arch Gerontol Geriatr. 2004 Jan-Feb; 38(1):61-8.
Score: 0.180
-
Cognitive functioning in late-life schizophrenia: a comparison of elderly schizophrenic patients and patients with Alzheimer's disease. Am J Psychiatry. 1996 Oct; 153(10):1274-9.
Score: 0.109
-
The use of benzodiazepines in the management of behavioral symptoms in demented patients. Psychiatr Clin North Am. 1991 Jun; 14(2):375-84.
Score: 0.075
-
The treatment of cognitive impairment in Alzheimer's disease: beyond the cholinergic approach. Psychiatr Clin North Am. 1991 Jun; 14(2):461-82.
Score: 0.075
-
Diagnostic and pharmacological approaches in Alzheimer's disease. Drugs Aging. 1991 Mar; 1(2):144-62.
Score: 0.074
-
Cholinergic strategies in the treatment of Alzheimer's disease. Acta Psychiatr Scand Suppl. 1991; 366:47-51.
Score: 0.073
-
Combined administration of physostigmine and clonidine to patients with dementia of the Alzheimer type: a pilot safety study. Alzheimer Dis Assoc Disord. 1989; 3(4):224-7.
Score: 0.064
-
Endocrine changes in Alzheimer's disease. Endocrinol Metab Clin North Am. 1988 Mar; 17(1):149-57.
Score: 0.060
-
Factor analysis of the Cohen-Mansfield Agitation Inventory in three large samples of nursing home patients with dementia and behavioral disturbance. Am J Geriatr Psychiatry. 2005 Nov; 13(11):991-8.
Score: 0.051
-
Type 2 diabetes is negatively associated with Alzheimer's disease neuropathology. J Gerontol A Biol Sci Med Sci. 2005 Apr; 60(4):471-5.
Score: 0.049
-
Relationship between body height and dementia. Am J Geriatr Psychiatry. 2005 Feb; 13(2):116-23.
Score: 0.049
-
The role of cardiovascular risk factors in Alzheimer's disease. CNS Spectr. 2003 Nov; 8(11):824-33.
Score: 0.044
-
Galantamine provides sustained benefits in patients with 'advanced moderate' Alzheimer's disease for at least 12 months. Dement Geriatr Cogn Disord. 2003; 15(2):79-87.
Score: 0.042
-
A cross-sectional study of lipids and ApoC levels in Alzheimer's patients with and without cardiovascular disease. J Gerontol A Biol Sci Med Sci. 2002 Nov; 57(11):M757-61.
Score: 0.041
-
Economic cost of Alzheimer disease in Israel. Alzheimer Dis Assoc Disord. 2002 Apr-Jun; 16(2):73-80.
Score: 0.040
-
Alzheimer disease and related neurodegenerative diseases in elderly patients with schizophrenia: a postmortem neuropathologic study of 100 cases. Arch Gen Psychiatry. 1998 Mar; 55(3):205-11.
Score: 0.030
-
Germline mutational analysis of presenilin 1 and APP genes in Jewish-Israeli individuals with familial or early-onset Alzheimer disease using denaturing gradient gel electrophoresis (DGGE). Eur J Hum Genet. 1998 Mar-Apr; 6(2):176-80.
Score: 0.030
-
Apolipoprotein E4 in schizophrenia: a study of one hundred sixteen cases with concomitant neuropathological examination. Biol Psychiatry. 1997 Aug 15; 42(4):296-8.
Score: 0.029
-
Neuropeptide deficits in schizophrenia vs. Alzheimer's disease cerebral cortex. Biol Psychiatry. 1996 Jan 15; 39(2):82-91.
Score: 0.026
-
A pilot study of clonidine plus physostigmine in Alzheimer's disease. Dementia. 1994 Sep-Oct; 5(5):243-6.
Score: 0.024
-
Galanin-like immunoreactivity is increased in the postmortem cerebral cortex from patients with Alzheimer's disease. J Neurochem. 1994 Apr; 62(4):1516-23.
Score: 0.023
-
A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry. 1994 Mar; 151(3):390-6.
Score: 0.023
-
Alzheimer's-disease-related protein in geriatric schizophrenic patients with cognitive impairment. Am J Psychiatry. 1993 Nov; 150(11):1726-7.
Score: 0.022
-
Selective loss of dopamine D3-type receptor mRNA expression in parietal and motor cortices of patients with chronic schizophrenia. Proc Natl Acad Sci U S A. 1993 Oct 01; 90(19):8942-6.
Score: 0.022
-
A pilot study of oral physostigmine plus yohimbine in patients with Alzheimer disease. Alzheimer Dis Assoc Disord. 1993; 7(2):98-104.
Score: 0.021
-
Deterioration on the Blessed test in Alzheimer's disease: longitudinal data and their implications for clinical trials and identification of subtypes. Psychiatry Res. 1992 May; 42(2):101-10.
Score: 0.020
-
Agitation and postdexamethasone cortisol levels in Alzheimer's disease. Am J Psychiatry. 1992 Apr; 149(4):546-8.
Score: 0.020
-
CSF somatostatin in Alzheimer's disease, depressed patients, and control subjects. Biol Psychiatry. 1988 Oct; 24(6):710-2.
Score: 0.016
-
Clinical predictors of course for Alzheimer patients in a longitudinal study: a preliminary report. Psychopharmacol Bull. 1988; 24(3):458-62.
Score: 0.015
-
Increased concentrations of presynaptic proteins in the cingulate cortex of subjects with schizophrenia. Arch Gen Psychiatry. 1997 Jun; 54(6):559-66.
Score: 0.007
-
Cortical cholinergic markers in schizophrenia. Schizophr Res. 1994 May; 12(2):137-44.
Score: 0.006
-
Severe cognitive impairment in elderly schizophrenic patients: a clinicopathological study. Biol Psychiatry. 1993 Feb 15; 33(4):255-60.
Score: 0.005
-
Assessment of dementia in elderly schizophrenics with structured rating scales. Schizophr Res. 1992 Apr; 7(1):85-90.
Score: 0.005